{"analyses":[{"ciLowerLimit":"0.985","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.104","groupDescription":"All analyses based on final DBL were descriptive only.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"1.749"},{"ciLowerLimit":"0.825","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.647","groupDescription":"All analyses based on final DBL were descriptive only.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"1.478"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.4","upperLimit":"50.6","value":"40.7"},{"groupId":"OG001","lowerLimit":"27.7","upperLimit":"46.5","value":"36.7"},{"groupId":"OG002","lowerLimit":"20.0","upperLimit":"37.9","value":"28.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"106"}],"units":"Participants"}],"description":"ORR as assessed by IRC per RECIST 1.1 was defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 1: Cemiplimab + Chemotherapy"},{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab","id":"OG001","title":"Part 1: Cemiplimab+AbbrevChemo+Ipilimumab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG002","title":"Part 1: Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Part 1 participants only","reportingStatus":"POSTED","timeFrame":"Up to 32 months","title":"Part 1: Objective Response Rate (ORR) Per IRC","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}